Sanofi Expands Diabetes Portfolio with $2.9 Billion Deal for Provention Bio
TZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read moreTZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read morePharma giant Pfizer and American biotech company Seagen officially announced on Monday that they have reached a conditional merger agreement
Read moreThe worldwide product rights for the Astelas’ top systemic antifungal agent Mycamine® (micafungin sodium, known as Funguard® in Japan) have
Read moreThe acquisition agreement is set to expand Aegis’s toxicology portfolio, while HealthTrackRx expands its PCR infectious disease testing. Aegis Sciences
Read moreLonza and Context Therapeutics, a US-based clinical-stage biopharmaceutical company advancing therapeutics for solid tumors, announced that they have reached a
Read moreBoehringer Ingelheim and Click Therapeutics announced on December 19, that they will expand their existing collaboration to develop and commercialize
Read moreBiosynth Carbosynth, critical materials supplier to the life science industry, has announced the signing of an agreement to acquire EUCODIS
Read morePfizer and Biohaven Pharmaceutical Holding Company announced on Tuesday, that they have struck an agreement under which Pfizer will acquire
Read moreBioEcho Life Sciences GmbH, an innovative manufacturer of nucleic acid purification solutions for molecular diagnostics and life sciences research, announced
Read moreMedix Biochemica has acquired DNA polymerases specialist biotechnology firm myPOLS Biotec thereby expanding its molecular diagnostics business unit. • Medix
Read more